Since CAXII is usually poorly expressed in most healthy cells [5], the use of CAXII inhibitors, may provide a selective tumor-targeting approach when administered with standard chemotherapeutic drugs to patients with drug resistant tumors. This evidence concerns the gene CA12 and neoplasm.